Roche has received approval from the U.S. Food and Drug Administration (FDA) for Enspryng (satralizumab) to treat adults with thyroid eye disease (TED). The approval introduces the first and only at-home subcutaneous treatment option for adults living with this rare autoimmune condition, giving patients greater flexibility in managing their disease.
Announced on October 16, 2026, the approval is based on results from the Phase 3 SatraGO-1 and SatraGO-2 clinical trials. The studies evaluated the safety and effectiveness of satralizumab in people with thyroid eye disease, a condition that can cause eye bulging, double vision, facial changes and, in severe cases, vision-threatening complications.
In the SatraGO-2 study, Enspryng demonstrated a significant reduction in proptosis, or eye bulging, and improvements in diplopia, commonly known as double vision. The results also showed a favorable safety profile, regardless of how active the disease was or how long patients had been living with the condition.
Enspryng is a monoclonal antibody that targets the interleukin-6 receptor (IL-6R), a protein involved in inflammation and immune system activity. By blocking IL-6 signaling, the treatment is designed to address processes involved in thyroid eye disease.
One of the key benefits of the FDA approval is the option for at-home administration. Enspryng is given as a subcutaneous injection, meaning it is injected under the skin. During the maintenance phase, the treatment can be administered every four weeks by patients or caregivers after receiving training from a healthcare professional.
This approach could offer greater convenience for patients who need ongoing treatment and reduce the need for frequent visits to healthcare facilities for infusion-based therapies.
Thyroid eye disease is an autoimmune condition often associated with thyroid disorders. It develops when the immune system mistakenly attacks tissues around the eyes, leading to inflammation, swelling and other symptoms that can affect vision and quality of life. Roche estimates that the condition affects approximately 155 people per 100,000 in the United States.
Roche said the approval represents an important step in expanding treatment options for people living with thyroid eye disease. The company believes that the availability of a targeted treatment that can be administered at home could help address some of the practical challenges associated with long-term disease management.
The approval further strengthens Roche’s ophthalmology portfolio as the company continues to develop treatments for serious eye conditions. Its research efforts cover several areas, including retinal diseases, diabetic eye conditions and autoimmune disorders affecting vision.
With the FDA decision, Enspryng offers a new treatment option for adults with thyroid eye disease, combining targeted IL-6 receptor inhibition with the convenience of at-home administration.